Oral itraconazole for the treatment of giant tufted angioma with hair loss arising during pregnancy: A case report

Wu, Wei; Shi, Jianqiang; Li, Zhaojun; Ding, Li; Dou, Shuhui; Pradhan, Sushmita; Ran, Xin; Ran, Yuping

doi:10.1111/1346-8138.15144

Cited by 3 publications

(2 citation statements)

References 4 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A favorable outcome was achieved as the lesions faded by 80%-100% after 2-9 wk of itraconazole treatment (5 mg/kg/d), although minor digestive symptoms, such as diarrhea, appeared. Later, the same team reported positive results of a giant tufted angioma, which faded within 3 mo of oral itraconazole treatment[ 12 ]. The liver function and blood test were normal during the treatment, and conditions continued to improve 6 mo after withdrawal of the medicine.…”

Section: Discussionmentioning

confidence: 99%

Itraconazole therapy for infant hemangioma: Two case reports

Liu

Wang

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Infantile hemangiomas (IHs) are the most common childhood benign tumors, showing distinctive progression characteristics and outcomes. Due to the high demand for aesthetics among parents of IH babies, early intervention is critical in some cases. β-Adrenergic blockers and corticosteroids are first-line medications for IHs, while itraconazole, an antifungal medicine, has shown positive results in recent years. CASE SUMMARY In the present study, itraconazole was applied to treat two IH cases. The therapeutic course lasted 80-90 d, during which the visible lesion faded by more than 90%. Moreover, no obvious side effects were reported, and the compliance of the baby and parents was desirable. CONCLUSION Although these outcomes further support itraconazole as an effective therapeutic choice for IHs, large-scale clinical and basic studies are still warranted to improve further treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Itraconazole therapy for infant hemangioma: Two case reports

Liu

Wang

et al. 2021

WJCC

View full text Add to dashboard Cite

show abstract

“…She was prescribed 400 milligrams (mg) a day, orally, for 3 months. This therapy resulted in the cessation of pain after a few days, followed by hair regrowth and a significant reduction in tumour size [8].…”

mentioning

confidence: 99%

Itraconazole as a new pharmacotherapy method in haemangiomas

Gałązka¹,

Leis²,

Mazur³

et al. 2021

pdia

View full text Add to dashboard Cite

Reactive cutaneous capillary endothelial proliferation treated successfully by oral itraconazole: A case report

Yao,

Zhu,

Luo

et al. 2024

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

A 39-year-old female visited our clinic, complaining of multiple red plaques all over her body for 2 months in April 2023. Two months ago, she received intravenous camrelizumab (Cam) 200 mg treating diffuse large B-cell lymphoma (DL-BL). Several days later, red papules appeared on her scalp, face, neck, and chest, which gradually involved the bilateral upper limbs. One month ago, she received the same injection, after which the lesions rapidly enlarged in size and increased in number. Even after stopping Cam for 2 months, the rashes continued to spread and bleed easily. The patient was diag-

show abstract

Oral itraconazole for the treatment of giant tufted angioma with hair loss arising during pregnancy: A case report

Abstract: Journal of Dermatology 2020; 47: e35-e72 e35

Cited by 3 publications

References 4 publications

Itraconazole therapy for infant hemangioma: Two case reports

Itraconazole therapy for infant hemangioma: Two case reports

Itraconazole as a new pharmacotherapy method in haemangiomas

Reactive cutaneous capillary endothelial proliferation treated successfully by oral itraconazole: A case report

Contact Info

Product

Resources

About